3.2 Sedatives, Hypnotics, Anxiolytics, and Cross-Tolerance

The sedative-hypnotic class and cross-tolerance

Sedatives, hypnotics, and anxiolytics depress the CNS, mostly by enhancing GABA activity — the same broad mechanism as alcohol. That shared mechanism is why cross-tolerance is a high-yield exam term: a person tolerant to alcohol is often tolerant to benzodiazepines and barbiturates, and the reverse holds. Cross-tolerance is also why physicians can use long-acting benzodiazepines to treat alcohol withdrawal — the drugs substitute for one another at the receptor.

Intoxication looks like alcohol without the odor: drowsiness, slowed thinking, slurred speech, ataxia, impaired memory, falls, poor driving judgment, and reduced capacity to participate in treatment. Benzodiazepines are also notable for causing anterograde amnesia (the inability to form new memories during intoxication), which is why some are used in drug-facilitated assault. The CADC exam does not expect prescribing-level detail — it expects you to recognize CNS depression, safety risk, withdrawal danger, and the need for referral when symptoms exceed counseling scope.

Because many clients arrive on legitimately prescribed benzodiazepines for anxiety, insomnia, or panic, the exam tests your ability to assess pattern rather than assume a problem from the prescription alone. Escalating doses, early refills, using a partner's pills, combining with alcohol, and morning withdrawal symptoms are the behavioral signals that move a prescribed medication into a possible substance-use concern.

Overdose risk and life-threatening withdrawal

Overdose: benzodiazepines alone rarely kill a healthy adult, but barbiturates have a narrow therapeutic window and can be lethal alone. The real danger the exam emphasizes is combination: sedatives plus alcohol or opioids stack respiratory depression rather than simply adding, producing a multiplicative overdose risk. Benzodiazepines are detected in a large share of opioid-overdose deaths for this reason.

Withdrawal is the other life-threatening point. Like alcohol, sedative-hypnotic withdrawal can produce seizures and delirium and must be tapered under medical supervision — abrupt cessation ("cold turkey") is dangerous.

Withdrawal features include rebound anxiety, insomnia, tremor, sweating, agitation, perceptual disturbances, and — most dangerously — grand mal seizures and delirium. A subset of clients develop protracted withdrawal (sometimes called benzodiazepine-induced neurological dysfunction), with anxiety, insomnia, and perceptual symptoms lingering for weeks to months, which can be mistaken for relapse or a primary anxiety disorder.

The exam may not name the drug class directly: it may describe someone who stopped nightly pills used for months and now appears shaky and disoriented. Treat that as a probable medical-referral item, not a counseling-only one — a medically supervised taper (gradual dose reduction, often switching to a long-acting agent) is the standard, never abrupt cessation.

Scope, assessment, and exam traps

Scope matters. CADCs can educate at a general level, support motivation, coordinate care, document observations, and encourage communication with qualified prescribers. CADCs do not prescribe, change doses, supervise detox independently, or promise a client can quit at home safely.

Applied scenario: a client says she takes extra anxiety medication with wine because the medication alone no longer works and now feels shaky on mornings she skips it. The strongest CADC response is not to advise a taper or sudden stop. It is to assess amount, frequency, last use, prescriber involvement, current impairment, overdose risk, and withdrawal history, then refer or coordinate within consent and agency policy. The morning shakiness signals physical dependence and possible withdrawal — a medical, not motivational, concern.

A useful counseling frame is that the client may be caught between a real anxiety or sleep problem and a medication that now causes harm. Validating the original distress while naming the current risk reduces defensiveness and keeps the client engaged for the medical referral that the situation actually requires.

Focused assessment questions:

• What is prescribed, by whom, and at what dose? Are you taking more than directed?
• How often, by what route, and when was your last dose?
• Do you combine it with alcohol, opioids, or other substances?
• Have you ever had a seizure, blackout, or severe symptoms when stopping?
• Are you using it to cope, to sleep, or to manage other substance effects?

Exam traps: (1) choosing the "empowering" answer that advises abrupt discontinuation — stopping sedatives suddenly can trigger seizures; (2) assuming legal prescription status removes risk — misuse, dependence, and unsafe combinations are testable even when the drug was prescribed; (3) labeling a client "drug-seeking" without a specific behavioral fact in the stem. Use neutral language: prescribed medication, taking more than directed, using with alcohol, using to cope.

For one-best-answer items, pick the safest action within role boundaries — observe and document impairment, ask about last use and co-use, consult, and refer for medical evaluation when withdrawal or overdose risk appears.